| Literature DB >> 22118407 |
Rick M Maizels1, Katherine A Smith.
Abstract
Infectious agents have intimately co-evolved with the host immune system, acquiring a portfolio of highly sophisticated mechanisms to modulate immunity. Among the common strategies developed by viruses, bacteria, protozoa, helminths, and fungi is the manipulation of the regulatory T cell network in order to favor pathogen survival and transmission. Treg activity also benefits the host in many circumstances by controlling immunopathogenic reactions to infection. Interestingly, some pathogens are able to directly induce the conversion of naive T cells into suppressive Foxp3-expressing Tregs, while others activate pre-existing natural Tregs, in both cases repressing pathogen-specific effector responses. However, Tregs can also act to promote immunity in certain settings, such as in initial stages of infection when effector cells must access the site of infection, and subsequently in ensuring generation of effector memory. Notably, there is little current information on whether infections selectively drive pathogen-specific Tregs, and if so whether these cells are also reactive to self-antigens. Further analysis of specificity, together with a clearer picture of the relative dynamics of Treg subsets over the course of disease, should lead to rational strategies for immune intervention to optimize immunity and eliminate infection.Entities:
Mesh:
Year: 2011 PMID: 22118407 PMCID: PMC7150045 DOI: 10.1016/B978-0-12-387827-4.00003-6
Source DB: PubMed Journal: Adv Immunol ISSN: 0065-2776 Impact factor: 3.543
Tregs in viral infections
| Retroviruses | ||
| FIV | Tregs promote progression and restrain anti-viral responses | |
| Friend retrovirus | Expansion of Tregs | |
| Tregs suppress CD8 antiviral immunity | ||
| Nonantigen-specific Tregs control pathology in RAG model | ||
| HIV | Treg numbers correlate with viral load but decline in persistent viremia | |
| CD25+ Tregs maintain suppressive capacity in infection | ||
| Tregs reduce activation of and inhibit infection of effector T cells | ||
| gp120 binding to CD4 may activate Tregs T cells recognising protective HLA allele specificities not suppressed by Tregs | ||
| LCMV | Blocks diabetes through Tregs | |
| Superantigen-mediated expansion of Tregs | ||
| MAIDS | Tregs promote infection, ablation blocks | |
| MMTV | Tregs reduce viral load at outset, increase later. Superantigen-specific Tregs | |
| SIV | Foxp3 in both CD25− and CD25+ T cells correlates with high viremia | |
| RNA viruses | ||
| Hepatitis C | Elevated functional Foxp3+ Tregs | |
| Disease resolution associated with reduced Treg activity | ||
| Influenza A | CD25+ depletion raises CD8+ response | |
| MHV coronavirus | Treg depletion can be fatal | |
| Tregs reduce demyelination | ||
| Viral epitope-specific Tregs | ||
| Rhinovirus in humans | Induce IL-35+Foxp3− Tregs via DCs | |
| RSV | Tregs dampen response and limit pathology but depletion does not change viral load | |
| DNA viruses | ||
| CMV | CD25+ Tregs suppress CMV response | |
| EBV | CD8+ Tregs in active infection | |
| Hepatitis B | CD4+FoxP3+ Treg numbers correlate with viral load and serum TGF-β | |
| HSV-1 | Tregs expand in infection, restraining responsiveness and pathology | |
| Ocular pathology controlled by Tregs (and IL-10), including | ||
| HSV-2 | Treg ablation results in loss of immunity through reduced effectors at site of infection | |
| Human papillomavirus 16 | CD25+ Tregs correlate with persistent infection | |
| Vaccinia | CD25+ depletion raises CD8+ response | |
Tregs in bacterial infections
| Mycobacteria | ||
| | Elevated pulmonary Foxp3+ cells, bacterial load unchanged by anti-CD25 depletion | |
| | Elevated FOXP3+ cells, inversely correlating with immunity, reduced after treatment | |
| | Tregs expand, increase bacterial load | |
| Tregs delay priming and migration of effectors | ||
| Mtb-specific Tregs activated | ||
| | Induce Tregs, block allergy | |
| Other intracellular | ||
| | Tregs block protective immunity | |
| | Tregs stimulated but no correlation with disease | |
| | Tregs suppress memory CD8+ T cells | |
| No antigen-specific Tregs | ||
| Respiratory | ||
| | Tr1 generation through filamentous hemagglutinin | |
| Gastrointestinal pathogens | ||
| | Tregs enriched in lesions | |
| | Treg expansion in the mucosa, CD25 depletion reduces bacterial load but generates pathology | |
| Infection-related Tregs suppress airway allergy | ||
| | Treg depletion or anti-CTLA-4 boosts clearance and memory | |
| Commensal bacteria | ||
| | Drives Treg expansion, through PSA binding to TLR2 | |
| | Induction of Tregs, bystander suppression of inflammation following mucosal | |
| | Mediates Treg induction through TGF-β, protects against DSS colitis | |
| | Tr1-like IL-10-producing cells block gut inflammation | |
| | CD8+CD28+ suppressive Tregs producing IL-10 and TGF-β | |
Tregs in protozoal infections
| Human malaria | ||
| | Elevated CD25+ and FOXP3+ in infection, correlate with parasite load, and in cord blood of newborns to infected mothers | |
| FOXP3+ numbers expand in severe malaria, decline following treatment | ||
| Human patients have high FOXP3+ Tregs | ||
| Bystander FOXP3 (hi) induction in human T cells | ||
| Human placenta Treg induction | ||
| | Elevated FOXP3+ in infection | |
| Murine malaria | ||
| | CD25 depletion alleviates cerebral malaria (CM) | |
| Foxp3+ depletion does not alter CM while expansion through IL-2/IL-2R complexes protects from CM | ||
| | Foxp3 overexpression compromises protection; Tregs are anti-inflammatory | |
| | Anti-CD25 prevents malaria immune evasion through TLR9 signaling | |
| IL-10 and anti-CD25 in malaria | ||
| Early CD25+ Treg expansion in susceptible strain | ||
| Leishmaniasis | ||
| | Human lesions have FOXP3+ | |
| | CD40-low DCs induce Tregs, exacerbate infection | |
| Human lesions have high FOXP3+, abated with treatment | ||
| | Human lesions have high FOXP3+ | |
| | Elevated Foxp3+CD103+ in infection | |
| | Tregs maintain low-level infection and protective immunity, require CD103 to access infection site and suppress | |
| Treg depletion raises Th2 response and susceptibility; Tregs reactivate infection | ||
| Toxoplasmosis | ||
| | Tregs reduce parasite-induced abortion in pregnant mice | |
| Trypanosomiasis | ||
| | Foxp3+ Tregs suppress protective CD8+ NKT cells | |
| | Natural Tregs suppress CD4+, CD8+, and macrophage inflammation | |
| | Increased FOXP3+ in human infection, and CD25+ Tregs prolong survival in mice | |
Tregs in helminth infections
| Filarial nematodes | ||
| | Induces Foxp3 expression, including in DO11.10 T cells | |
| | CD25 depletion raises Th2 response | |
| | Tregs maintain infection through CTLA-4 and inhibit allergy | |
| | TGF-β-producing clones from human infection site | |
| | Raised FOXP3+ T cells in infected patients | |
| Intestinal nematodes | ||
| | High FOXP3 expression in uninflamed mucosa of UC patient | |
| | ||
| | Treg depletion reduces worm burden | |
| | In HTLV-1 co-infection, excessive FOXP3+ Tregs, suppression of IL-5 and high worm burdens | |
| | Tissue-migrating larvae induce Foxp3 in mice | |
| | IL-10− Tregs restrain Th2 responses | |
| | IL-10− Tregs restrain Th2 responses | |
| Trematodes (flatworms) | ||
| | Infection induces IL-10 and TGF-β from Tr1-like Tregs | |
| | FOXP3+ Tregs correlate with infection intensity in children | |
| | Egg antigens stimulate CD25+ suppression of airway allergy | |
| Treg induction via TLR2 ligation to HSP60 peptide | ||
| Anti-CD25 treatment reduces worm load | ||
| | IL-10− Tregs elevated CD103+, dampen IL-4 responses to eggs | |
| IL-10+ CD25+ Tregs control pathology, dampen Th1 allowing Th2 to expand | ||
| CD25+ Tregs expand through TLR2 to control pathology, upregulating CD103, CTLA4, and many other genes | ||
| Tregs induced by eggs, inhibit Th1 | ||
| Foxp3 expression decreases following chemotherapeutic cure | ||
| Pathology patients have fewer CD25high Tregs | ||
| Cestodes (tapeworms) | ||
| | Peritoneal T cells express high Foxp3 | |
Tregs in fungal infections
| Inflammation controlled by CD4+CD25+ Tregs | ||
| Early Th17 promoted by Tregs, but later immunity suppressed; Tregs neutralized by TLR2 ligation | ||
| Increased Foxp3+ Tregs and reduced T1D in NOD mice | ||
| Tregs suppress Th17 at site of infection | ||
| Onychomycosis | Higher CD4+CD25+ cell numbers in patients | |
| Tregs control inflammation and limit fungal clearance; migration of Foxp3+ Tregs to lesions | ||
| CD4+CD25+ Tregs suppress inflammation |
Figure 3.1Pathways of Treg induction and activation in infection.